TABLE 1.
Patient characteristics and voriconazole dosing
| Characteristic | |
|---|---|
| Patients, n | 69 |
| Median age, years (range) | 58 (19–80) |
| Male sex, % | 56.5 |
| Voriconazole courses, n | 71 |
| Inpatients | 61 (85.9) |
| Outpatients | 9 (12.7) |
| Unknown | 1 (1.4) |
| Diagnosis (% voriconazole courses) | |
| Acute myeloid leukemia | 63 (88.7) |
| Acute lymphoblastic leukemia | 4 (5.6) |
| Acute promyelocytic leukemia | 2 (2.8) |
| Aplastic anemia | 1 (1.4) |
| Myelodysplasia | 1 (1.4) |
| Invasive fungal infection (% voriconazole courses) | 42 (59.2) |
| Proven | 3 (4.2) |
| Probable | 9 (12.7) |
| Possible | 30 (42.3) |
| Voriconazole dosing | |
|
| |
| Loading dose | |
| Intravenous | 2 (2.8) |
| Oral | 25 (35.2) |
| No loading dose | 22 (31) |
| Unknown | 22 (31) |
| Oral maintenance dose | |
| 200 mg BID | 61 (85.9) |
| 250 mg BID | 1 (1.4) |
| 300 mg BID | 6 (8.5) |
| Unknown | 3 (4.2) |
| Maintenance dose, mg/kg | |
| 1–≤2 | 4 (5.9) |
| 2–≤3 | 33 (48.5) |
| 3–≤4 | 25 (35.2) |
| 4–≤5 | 6 (8.8) |
Data presented as n (%) unless otherwise indicated. BID Twice per day